Diseases /
Urothelial Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A malignant neoplasm derived from the transitional epithelium of the urinary tract (urinary bladder, ureter, urethra, or renal pelvis). It is frequently papillary. [1]
Urothelial carcinomas most frequently harbor alterations in TP53, KDM6A, KMT2D, FGFR3, and ARID1A [2].
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, FGFR3 Mutation, and KMT2D Mutation are the most common alterations in urothelial carcinoma [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for urothelial carcinoma, 1 is FDA-approved in at least one setting and 1 has NCCN guidelines in at least one setting [3].
Erdafitinib +
Disease is predicted to be sensitive: -
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
Note: Indicated for locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations and that progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. |
Clinical Trials
There are 230 clinical trials for urothelial carcinoma, of which 187 are open and 43 are completed or closed. Of the trials that contain urothelial carcinoma as an inclusion criterion, 2 are early phase 1 (2 open), 80 are phase 1 (61 open), 53 are phase 1/phase 2 (44 open), 72 are phase 2 (62 open), 1 is phase 2/phase 3 (0 open), 18 are phase 3 (16 open), and 4 are no phase specified (2 open).
FGFR3, FGFR1, and FGFR2 are the most frequent gene inclusion criteria for urothelial carcinoma clinical trials [3].
Pembrolizumab, nivolumab, and gemcitabine are the most common interventions in urothelial carcinoma clinical trials.
Significant Genes in Urothelial Carcinoma
ABL1 +
ABL1 is altered in 2.62% of urothelial carcinoma patients [2].
ABL1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ABL1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
AKT1 +
AKT1 is altered in 2.05% of urothelial carcinoma patients [2].
AKT1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
AKT2 +
AKT2 is altered in 2.89% of urothelial carcinoma patients [2].
AKT2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
AKT3 +
AKT3 is altered in 1.47% of urothelial carcinoma patients [2].
AKT3 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ARID1A +
ARID1A is altered in 27.44% of urothelial carcinoma patients [2].
ARID1A is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
ATM +
ATM is altered in 10.7% of urothelial carcinoma patients [2].
ATM is an inclusion eligibility criterion in 6 clinical trials for urothelial carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ATM status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 5 are phase 2 (5 open) [3].
ATR +
ATR is altered in 5.88% of urothelial carcinoma patients [2].
ATR is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].
ATRX +
ATRX is altered in 5.83% of urothelial carcinoma patients [2].
ATRX is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATRX status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
BAP1 +
BAP1 is altered in 5.11% of urothelial carcinoma patients [2].
BAP1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BAP1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
BARD1 +
BARD1 is altered in 2.59% of urothelial carcinoma patients [2].
BARD1 is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain BARD1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].
BRAF +
BRAF is altered in 4.78% of urothelial carcinoma patients [2].
BRAF is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and urothelial carcinoma as inclusion criteria, 3 are phase 2 (3 open) [3].
BRCA1 +
BRCA1 is altered in 5.82% of urothelial carcinoma patients [2].
BRCA1 is an inclusion eligibility criterion in 6 clinical trials for urothelial carcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRCA1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].
BRCA2 +
BRCA2 is altered in 8.2% of urothelial carcinoma patients [2].
BRCA2 is an inclusion eligibility criterion in 6 clinical trials for urothelial carcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRCA2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].
BRD4 +
BRD4 is altered in 2.82% of urothelial carcinoma patients [2].
BRD4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRD4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
BRIP1 +
BRIP1 is altered in 3.41% of urothelial carcinoma patients [2].
BRIP1 is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRIP1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].
C11ORF30 +
C11orf30 is altered in 0.87% of urothelial carcinoma patients [2].
C11orf30 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CCND1 +
CCND1 is altered in 10.61% of urothelial carcinoma patients [2].
CCND1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CDK12 +
CDK12 is altered in 6.35% of urothelial carcinoma patients [2].
CDK12 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDK12 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
CHEK1 +
CHEK1 is altered in 1.19% of urothelial carcinoma patients [2].
CHEK1 is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CHEK1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].
CHEK2 +
CHEK2 is altered in 3.91% of urothelial carcinoma patients [2].
CHEK2 is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CHEK2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].
CREBBP +
CREBBP is altered in 15.96% of urothelial carcinoma patients [2].
CREBBP is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CREBBP status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
CRKL +
CRKL is altered in 1.31% of urothelial carcinoma patients [2].
CRKL is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
DDR2 +
DDR2 is altered in 4.3% of urothelial carcinoma patients [2].
DDR2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
DOT1L +
DOT1L is altered in 4.1% of urothelial carcinoma patients [2].
DOT1L is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DOT1L status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
EGFR +
EGFR is altered in 4.38% of urothelial carcinoma patients [2].
EGFR is an inclusion eligibility criterion in 5 clinical trials for urothelial carcinoma, of which 4 are open and 1 is closed. Of the trials that contain EGFR status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (3 open) [3].
EP300 +
EP300 is altered in 13.19% of urothelial carcinoma patients [2].
EP300 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EP300 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
EPHA2 +
EPHA2 is altered in 0.54% of urothelial carcinoma patients [2].
EPHA2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is altered in 14.87% of urothelial carcinoma patients [2].
ERBB2 is an inclusion eligibility criterion in 9 clinical trials for urothelial carcinoma, of which 7 are open and 2 are closed. Of the trials that contain ERBB2 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (4 open) [3].
ERBB3 +
ERBB3 is altered in 10.77% of urothelial carcinoma patients [2].
ERBB3 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
ERBB4 +
ERBB4 is altered in 3.08% of urothelial carcinoma patients [2].
ERBB4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC2 +
ERCC2 is altered in 10.9% of urothelial carcinoma patients [2].
ERCC2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC3 +
ERCC3 is altered in 1.75% of urothelial carcinoma patients [2].
ERCC3 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC4 +
ERCC4 is altered in 2.4% of urothelial carcinoma patients [2].
ERCC4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC5 +
ERCC5 is altered in 1.92% of urothelial carcinoma patients [2].
ERCC5 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC6 +
ERCC6 is altered in 0.88% of urothelial carcinoma patients [2].
ERCC6 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCA +
FANCA is altered in 5.05% of urothelial carcinoma patients [2].
FANCA is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCA status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
FANCB +
FANCB is altered in 1.22% of urothelial carcinoma patients [2].
FANCB is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCB status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
FANCC +
FANCC is altered in 1.65% of urothelial carcinoma patients [2].
FANCC is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCC status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].
FANCD2 +
FANCD2 is altered in 6.82% of urothelial carcinoma patients [2].
FANCD2 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCD2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
FANCE +
FANCE is altered in 2.18% of urothelial carcinoma patients [2].
FANCE is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCE status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].
FANCF +
FANCF is altered in 1.75% of urothelial carcinoma patients [2].
FANCF is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCF status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
FANCG +
FANCG is altered in 1.7% of urothelial carcinoma patients [2].
FANCG is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCG status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].
FANCI +
FANCI is altered in 2.6% of urothelial carcinoma patients [2].
FANCI is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCI status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
FANCL +
FANCL is altered in 1.82% of urothelial carcinoma patients [2].
FANCL is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCL status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].
FANCM +
FANCM is altered in 6.1% of urothelial carcinoma patients [2].
FANCM is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCM status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
FGF1 +
FGF1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF10 +
FGF10 is altered in 3.64% of urothelial carcinoma patients [2].
FGF10 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF10 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF11 +
FGF11 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF11 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF12 +
FGF12 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF12 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF13 +
FGF13 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF13 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF14 +
FGF14 is altered in 0.38% of urothelial carcinoma patients [2].
FGF14 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF14 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF16 +
FGF16 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF16 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF17 +
FGF17 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF17 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF18 +
FGF18 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF18 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF19 +
FGF19 is altered in 10.41% of urothelial carcinoma patients [2].
FGF19 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGF19 status and urothelial carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
FGF2 +
FGF2 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF20 +
FGF20 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF20 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF21 +
FGF21 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF21 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF22 +
FGF22 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF22 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF23 +
FGF23 is altered in 1.23% of urothelial carcinoma patients [2].
FGF23 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF23 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF3 +
FGF3 is altered in 10.01% of urothelial carcinoma patients [2].
FGF3 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF3 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF4 +
FGF4 is altered in 10.73% of urothelial carcinoma patients [2].
FGF4 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGF4 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
FGF5 +
FGF5 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF5 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF6 +
FGF6 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF6 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF7 +
FGF7 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF7 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF8 +
FGF8 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF8 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FGF9 +
FGF9 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGF9 status and urothelial carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
FGFR1 +
FGFR1 is altered in 3.47% of urothelial carcinoma patients [2].
FGFR1 is an inclusion eligibility criterion in 13 clinical trials for urothelial carcinoma, of which 11 are open and 2 are closed. Of the trials that contain FGFR1 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 6 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (0 open), and 1 is phase 3 (1 open) [3].
FGFR2 +
FGFR2 is altered in 2.84% of urothelial carcinoma patients [2].
FGFR2 is an inclusion eligibility criterion in 11 clinical trials for urothelial carcinoma, of which 10 are open and 1 is closed. Of the trials that contain FGFR2 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 5 are phase 1/phase 2 (5 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].
FGFR3 +
FGFR3 is altered in 27.83% of urothelial carcinoma patients [2].
FGFR3 is an inclusion eligibility criterion in 16 clinical trials for urothelial carcinoma, of which 13 are open and 3 are closed. Of the trials that contain FGFR3 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 7 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (0 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [3].
Erdafitinib has evidence of efficacy in patients with FGFR3 mutation in urothelial carcinoma [3].
FGFR4 +
FGFR4 is altered in 2.0% of urothelial carcinoma patients [2].
FGFR4 is an inclusion eligibility criterion in 7 clinical trials for urothelial carcinoma, of which 6 are open and 1 is closed. Of the trials that contain FGFR4 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (2 open) [3].
FLT1 +
FLT1 is altered in 3.47% of urothelial carcinoma patients [2].
FLT1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT4 +
FLT4 is altered in 2.53% of urothelial carcinoma patients [2].
FLT4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FRK +
FRK is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRK status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
HRAS +
HRAS is altered in 4.61% of urothelial carcinoma patients [2].
HRAS is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
IKBKE +
IKBKE is altered in 1.37% of urothelial carcinoma patients [2].
IKBKE is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IKBKE status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
KRAS +
KRAS is altered in 5.52% of urothelial carcinoma patients [2].
KRAS is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
MAPK11 +
MAPK11 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MCPH1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
MDC1 +
MDC1 is altered in 4.69% of urothelial carcinoma patients [2].
MDC1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDC1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MDM2 +
MDM2 is altered in 9.31% of urothelial carcinoma patients [2].
MDM2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MDM4 +
MDM4 is altered in 1.18% of urothelial carcinoma patients [2].
MDM4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MEN1 +
MEN1 is altered in 1.82% of urothelial carcinoma patients [2].
MEN1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MEN1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MLH1 +
MLH1 is altered in 2.14% of urothelial carcinoma patients [2].
MLH1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
MLH3 +
MLH3 is altered in 2.79% of urothelial carcinoma patients [2].
MLH3 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MRE11A +
MRE11A is altered in 1.2% of urothelial carcinoma patients [2].
MRE11A is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MRE11A status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
MSH2 +
MSH2 is altered in 3.79% of urothelial carcinoma patients [2].
MSH2 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH2 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
MSH3 +
MSH3 is altered in 2.38% of urothelial carcinoma patients [2].
MSH3 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MSH6 +
MSH6 is altered in 3.99% of urothelial carcinoma patients [2].
MSH6 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
MTOR +
MTOR is altered in 5.04% of urothelial carcinoma patients [2].
MTOR is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MUTYH +
MUTYH is altered in 1.67% of urothelial carcinoma patients [2].
MUTYH is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MUTYH status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
NBN +
NBN is altered in 2.62% of urothelial carcinoma patients [2].
NBN is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NBN status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
NPM1 +
NPM1 is altered in 0.61% of urothelial carcinoma patients [2].
NPM1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
PALB2 +
PALB2 is altered in 3.49% of urothelial carcinoma patients [2].
PALB2 is an inclusion eligibility criterion in 5 clinical trials for urothelial carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PALB2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
PARP1 +
PARP1 is altered in 1.8% of urothelial carcinoma patients [2].
PARP1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PDGFRA +
PDGFRA is altered in 2.63% of urothelial carcinoma patients [2].
PDGFRA is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
PDGFRB +
PDGFRB is altered in 3.06% of urothelial carcinoma patients [2].
PDGFRB is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PIK3CA +
PIK3CA is altered in 20.84% of urothelial carcinoma patients [2].
PIK3CA is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PIK3CG +
PIK3CG is altered in 2.57% of urothelial carcinoma patients [2].
PIK3CG is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PIK3R1 +
PIK3R1 is altered in 1.94% of urothelial carcinoma patients [2].
PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PIK3R2 +
PIK3R2 is altered in 2.64% of urothelial carcinoma patients [2].
PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PMS1 +
PMS1 is altered in 2.2% of urothelial carcinoma patients [2].
PMS1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PMS2 +
PMS2 is altered in 2.48% of urothelial carcinoma patients [2].
PMS2 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PMS2 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
POLD1 +
POLD1 is altered in 3.88% of urothelial carcinoma patients [2].
POLD1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
POLE +
POLE is altered in 6.08% of urothelial carcinoma patients [2].
POLE is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
POLQ +
POLQ is altered in 6.81% of urothelial carcinoma patients [2].
POLQ is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLQ status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PPP2R1A +
PPP2R1A is altered in 2.0% of urothelial carcinoma patients [2].
PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PTEN +
PTEN is altered in 3.71% of urothelial carcinoma patients [2].
PTEN is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
RAD50 +
RAD50 is altered in 2.72% of urothelial carcinoma patients [2].
RAD50 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD50 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
RAD51 +
RAD51 is altered in 0.74% of urothelial carcinoma patients [2].
RAD51 is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].
RAD51B +
RAD51B is altered in 1.06% of urothelial carcinoma patients [2].
RAD51B is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51B status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
RAD51C +
RAD51C is altered in 2.35% of urothelial carcinoma patients [2].
RAD51C is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51C status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
RAD51D +
RAD51D is altered in 0.54% of urothelial carcinoma patients [2].
RAD51D is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51D status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
RAD52 +
RAD52 is altered in 0.96% of urothelial carcinoma patients [2].
RAD52 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD52 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RAD54L +
RAD54L is altered in 1.48% of urothelial carcinoma patients [2].
RAD54L is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD54L status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
RAF1 +
RAF1 is altered in 5.43% of urothelial carcinoma patients [2].
RAF1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RB1 +
RB1 is altered in 14.62% of urothelial carcinoma patients [2].
RB1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
RBBP8 +
RBBP8 is altered in 0.51% of urothelial carcinoma patients [2].
RBBP8 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RBBP8 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RECQL4 +
RECQL4 is altered in 4.23% of urothelial carcinoma patients [2].
RECQL4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RECQL4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RET +
RET is altered in 2.97% of urothelial carcinoma patients [2].
RET is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
RICTOR +
RICTOR is altered in 5.49% of urothelial carcinoma patients [2].
RICTOR is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ROS1 +
ROS1 is altered in 5.01% of urothelial carcinoma patients [2].
ROS1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
RPTOR +
RPTOR is altered in 2.76% of urothelial carcinoma patients [2].
RPTOR is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
SLX4 +
SLX4 is altered in 5.62% of urothelial carcinoma patients [2].
SLX4 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain SLX4 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
SMARCB1 +
SMARCB1 is altered in 2.06% of urothelial carcinoma patients [2].
SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
STAG2 +
STAG2 is altered in 12.73% of urothelial carcinoma patients [2].
STAG2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
STK11 +
STK11 is altered in 1.41% of urothelial carcinoma patients [2].
STK11 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain STK11 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
TP53 +
TP53 is altered in 45.06% of urothelial carcinoma patients [2].
TP53 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
TRNAK2 +
TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
TSC1 +
TSC1 is altered in 9.8% of urothelial carcinoma patients [2].
TSC1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TSC2 +
TSC2 is altered in 3.99% of urothelial carcinoma patients [2].
TSC2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
VEGFA +
VEGFA is altered in 1.97% of urothelial carcinoma patients [2].
VEGFA is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
VEGFB +
VEGFB is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
VEGFC +
VEGFC is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
XRCC1 +
XRCC1 is altered in 3.66% of urothelial carcinoma patients [2].
XRCC1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
XRCC2 +
XRCC2 is altered in 0.85% of urothelial carcinoma patients [2].
XRCC2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
XRCC3 +
XRCC3 is altered in 0.61% of urothelial carcinoma patients [2].
XRCC3 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC3 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
XRCC4 +
XRCC4 is altered in 1.22% of urothelial carcinoma patients [2].
XRCC4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
XRCC5 +
XRCC5 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC5 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
XRCC6 +
XRCC6 is altered in 2.44% of urothelial carcinoma patients [2].
XRCC6 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC6 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.